Loading...
XSHE
300086
Market cap399mUSD
Jul 09, Last price  
5.96CNY
1D
-0.50%
1Q
-27.32%
Jan 2017
-57.18%
IPO
-56.94%
Name

Honz Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300086 chart
P/E
P/S
5.82
EPS
Div Yield, %
Shrs. gr., 5y
0.21%
Rev. gr., 5y
-11.04%
Revenues
466m
-1.42%
135,846,194218,779,083314,451,808304,241,891368,780,279309,337,000408,538,464409,757,275471,474,595668,137,008882,744,8021,008,431,482921,642,902836,565,805836,565,804535,745,365535,745,365739,569,815472,817,734466,122,703
Net income
-230m
L+6.44%
49,524,79297,577,158139,317,546022,580,53314,852,93762,092,44968,197,18946,156,63355,537,65013,366,226-26,462,9769,339,25610,987,50410,987,5100-187,584,70711,529,869-216,208,514-230,138,658
CFO
121m
+69.66%
30,589,23862,607,03893,576,12879,893,9720109,459,62678,928,79873,930,32278,297,41590,883,87118,172,221157,658,19145,059,857011,329,33629,322,90570,693,70571,459,925121,242,064
Dividend
Aug 13, 20210.02 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Honz Pharmaceutical Co., Ltd. is a Chinese enterprise based in Guangzhou, primarily engaged in the creation, production, and commercialization of pharmaceutical drugs. While specializing in pediatric medications, the company also provides treatments for adults across a broad spectrum of health concerns. Its product offerings address conditions such as allergic responses, digestive and diarrheal issues, respiratory problems like coughs and flu, fevers, various infections, fungal ailments, pain relief, and endocrine disorders. Honz Pharmaceutical distributes its products to the market via an extensive network of agents and numerous retail sales outlets. The company officially adopted its current name in November 2016, having previously operated as HaiNan Honz Pharmaceutical Co.,Ltd.
IPO date
May 26, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT